Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Break B5-BM-NSCLC
2024-512684-31-00Phase 2Completed
- Sponsor
- Regensburg University Medical Center
- Start
- Aug 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, ipilimumab, bevacizumab-bvzr, carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Regensburg University Medical Center. Primary endpoints: Primary safety endpoint and Primary efficacy endpoint. Started Aug 2024; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on 2024-512684-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512684-31-00.